View Older Stories View More Recent Stories

Jun 24, 2025 07:01AM Revolution Medicines (RVMD) Enters Into $2B Flexible Funding Agreement with Royalty Pharma
Jun 23, 2025 09:01AM Revolution Medicines (RVMD) Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 Mutations
Jun 3, 2025 07:16AM Oppenheimer Reiterates Outperform Rating on Revolution (RVMD)
May 14, 2025 08:05AM Revolution Medicines (RVMD) Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating Daraxonrasib in Previously Treated Patients with RAS Mutant Non-Small Cell Lung Cancer
May 14, 2025 07:51AM Revolution (RVMD) PT Lowered to $72 at H.C. Wainwright
May 9, 2025 06:35AM Revolution Medicines (RVMD) Removed from Raymond James Analyst Current Favorites List
May 7, 2025 04:39PM Revolution Medicines, Inc. (RVMD) Reports Q1 Loss of $1.13
Apr 28, 2025 07:41AM Revolution Medicines (RVMD) Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer
Mar 31, 2025 04:13PM Revolution (RVMD) PT Lowered to $64 at Stifel
Mar 3, 2025 06:40AM Revolution (RVMD) PT Raised to $73 at H.C. Wainwright
Feb 27, 2025 07:43AM Revolution (RVMD) PT Lowered to $59 at Needham
Feb 26, 2025 04:22PM Revolution Medicines, Inc. (RVMD) Misses Q4 EPS by 13c
Jan 4, 2025 04:00PM 2025 Biopharma sector outlook
Jan 2, 2025 04:00PM Biotech outlook for 2025: Stifel
Jan 2, 2025 12:51PM Biopharma 2025 Preview: 'Piper Sandler Sees Lots of Upside Opportunity'
Jan 2, 2025 10:56AM Stifel Highlights Iovanace Biotherapeutics (IOVA) as 'Top Pick' in Biotech's 2025 Outlook Note
Dec 6, 2024 07:08AM Revolution (RVMD) PT Lowered to $62 at Needham
Dec 4, 2024 06:06AM Revolution Medicines (RVMD) Prices Upsized 14.13M Share Offering at $46/sh
Dec 3, 2024 06:50AM Revolution (RVMD) PT Raised to $87 at Guggenheim
Dec 2, 2024 04:31PM Revolution Medicines (RVMD) Announces Commencement of Public Offering of Common Stock
Dec 2, 2024 07:32AM Revolution Medicines (RVMD) Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio
Nov 7, 2024 08:26AM Revolution (RVMD) PT Raised to $70 at Piper Sandler
Nov 6, 2024 04:19PM Revolution Medicines, Inc. (RVMD) Misses Q3 EPS by 5c
Nov 4, 2024 06:46AM Revolution (RVMD) PT Raised to $62 at H.C. Wainwright
Oct 28, 2024 08:21AM Revolution (RVMD) PT Raised to $60 at Oppenheimer
Oct 28, 2024 07:18AM Needham Reiterates Buy Rating on Revolution (RVMD)
Oct 25, 2024 07:10AM TD Cowen Reiterates Buy Rating on Revolution (RVMD)
Oct 25, 2024 06:02AM Revolution Medicines (RVMD) Presents Initial Data from RMC-9805 Monotherapy Study
Oct 15, 2024 07:00PM JPMorgan just refreshed its Analysts Focus List and added these 4 stocks
Oct 15, 2024 06:16AM Oppenheimer Reiterates Outperform Rating on Revolution (RVMD)
Oct 10, 2024 07:23AM Piper Sandler Reiterates Overweight Rating on Revolution (RVMD)
Oct 7, 2024 07:05AM Needham Reiterates Buy Rating on Revolution (RVMD)
Sep 30, 2024 08:30AM JPMorgan refreshed its U.S. Analyst Focus List, adding these six stocks
Sep 25, 2024 11:00AM JPM just refreshed its US Analyst Focus List, adding these 5 stocks
Sep 17, 2024 07:13AM Piper Sandler Reiterates Overweight Rating on Revolution (RVMD)
Aug 8, 2024 07:50AM Revolution (RVMD) PT Lowered to $61 at Needham
Aug 7, 2024 04:12PM Revolution Medicines, Inc. (RVMD) Misses Q2 EPS by 4c
Jul 16, 2024 07:24AM TD Cowen Reiterates Buy Rating on Revolution (RVMD)
Jul 16, 2024 07:15AM Revolution (RVMD) PT Raised to $62 at Needham
Jul 16, 2024 06:43AM Revolution (RVMD) PT Raised to $56 at H.C. Wainwright
Jul 16, 2024 05:52AM Revolution (RVMD) PT Raised to $55 at JPMorgan
Jul 16, 2024 05:52AM Revolution (RVMD) PT Raised to $55 at Oppenheimer
Jul 16, 2024 05:47AM Revolution (RVMD) PT Raised to $55 at BofA Securities
Jul 15, 2024 04:03PM Revolution (RVMD) PT Raised to $73 at Jefferies
Jul 15, 2024 01:42PM Revolution (RVMD) PT Raised to $57 at Stifel
Jul 15, 2024 08:53AM Revolution Medicines (RVMD) provides pipeline updates
Jul 12, 2024 02:53AM Barclays Starts Revolution (RVMD) at Overweight
Jul 11, 2024 12:01PM Revolution Medicines (RVMD) Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer
Jul 8, 2024 02:06AM Jefferies Starts Revolution (RVMD) at Buy
Jun 25, 2024 10:40AM TD Cowen Reiterates Buy Rating on Revolution (RVMD)
View More Recent Stories View Older Stories